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Introduction
In the last decades, cancer research has been focused on 
identifying novel targets for therapy, especially on trying to 
develop new strategies to fight untreatable tumors. Almost 
20 years ago, ion channels were proposed as potential tar-
gets: they are often aberrantly expressed in cancer tissues 
compared to healthy ones, and, importantly, there are many 
pharmacological tools already available to manipulate 
them. Ion channels have been demonstrated to contribute to 
the acquirement of several hallmarks of cancer cells (Hana-
han and Weinberg 2011): metabolic re-programming (e.g., 
Andersen et al. 2014; Leanza et al. 2013a, 2014b), limit-
less proliferative potential (Urrego et al. 2014; Pardo and 
Stühmer 2014), apoptosis resistance (Wang 2004; Hoff-
mann and Lambert 2014), stimulation of neo-angiogenesis 
(Munaron 2015) as well as cell migration and invasiveness 
(Litan and Langhans 2015; Djamgoz and Onkal 2013). 
In recent years, not only plasma membrane channels but 
also intracellular ones have been related to the control of 
some typical features in cancer cells (Leanza et al. 2013a). 
Inside the cell, ion channels are expressed in several orga-
nelles (Xu et al. 2015): mitochondria, endoplasmic reticu-
lum, nucleus, lysosome, Golgi apparatus, peroxisomes and 
endosomes. Most of the identified “oncogenic” intracellu-
lar channels are located in the outer or inner mitochondrial 
membrane (OMM and IMM), since this organelle is a key 
point of control of important hallmarks of cancer, such as 
ATP-linked metabolism and apoptotic cell death. Another 
relevant intracellular location is the endoplasmic reticulum 
(ER): ion channels and transporters of the ER modulate 
the cytosolic Ca2+ concentration by controlling the uptake 
and release of calcium from this intracellular store and thus 
impact several cellular pathways implicated in the deter-
mination of cell fate as well in cell metabolism. Figure 1 
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summarizes the intracellular channels that have been linked 
to tumorigenesis or have been identified as possible targets.
The relevance of studying oncogenic channels is under-
lined by recent studies demonstrating that their pharmaco-
logical modulation can reduce tumor growth even in vivo 
in preclinical models of brain, lung, stomach, colon, blood, 
cervix, bladder, skin, prostate, breast, esophagus and oral 
cavity cancers (Leanza et al. 2015a).
In this review, we discuss intracellular channels whose 
altered expression has been related to cancer development 
or progression. Furthermore, we mention cases where phar-
macological modulation of these channels points toward a 
possibility of exploiting them for treatment.
Mitochondrial channels
Voltage‑dependent anion channel (VDAC)
The identification of voltage-dependent anion channels 
(VDACs) succeeded using electrophysiology and elec-
tron microscopy, since it was demonstrated that the outer 
mitochondrial membrane (OMM) leak was due to unique 
anion-selective channels, which transport cations, such as 
Ca2+, as well as many charged and non-charged metabo-
lites, with selectivity for anions over cations being modi-
fied by membrane voltage (Colombini and Mannella 2012).
VDAC mediates metabolic cross-talk between the 
mitochondria and the rest of the cell (Shoshan-Barmatz 
et al. 2010; Shoshan-Barmatz and Mizrachi 2012; Reddy 
2013), is a key player in the regulation of mitochondria-
mediated apoptosis and is implicated in cancer and neu-
rodegenerative disorders (Shoshan-Barmatz et al. 2010; 
Shoshan-Barmatz and Golan 2012; Shoshan-Barmatz 
and Mizrachi 2012; Reddy 2013). In mammals, three ver-
sions of VDAC have been identified, VDAC1, VDAC2 and 
VDAC3 (Blachly-Dyson and Forte 2001), which have simi-
lar molecular weights (30–35 kDa), share approximately 
70 % identity and show structural and functional homol-
ogy. The three isoforms are nearly ubiquitous in all tissue 
types, with VDAC2 and VDAC3 expression being lower 
than VDAC1 (Messina et al. 2012). Recombinant VDAC1 
and VDAC2 form channels upon reconstitution into a lipid 
bilayer (BLM) (Xu et al. 1999). Recently, also hVDAC3 
was shown to give rise to channel activity in BLM dis-





























Fig. 1  Intracellular ion channels are expressed in several subcellular compartments, such as the nucleus, endoplasmic reticulum, Golgi appara-
tus, lysosome and mitochondria. Ion channels, whose role in cancer development and/or progression has been demonstrated, are stained in green
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contrast to VDAC1 (4 nS in 1 M KCl) (Checchetto et al. 
2014). VDAC3 has recently been proposed to act as a redox 
sensor in the cells, given that its function depends on the 
redox state of critical cysteine residues that face the inter-
membrane space (Reina et al. 2016). Interestingly, there are 
many cases where VDACs have been mutated in various 
cancer tissues, although the relevance of these mutations 
in the context of tumor progression is still unclear (Naghdi 
and Hajnóczky 2016).
Besides its presence in the OMM, VDAC1 has also been 
localized by immunofluorescence, flow cytometry and EM 
immunogold labeling in other cell compartments, such as 
the plasmamembrane (De Pinto et al. 2010), sarcoplas-
mic reticulum of skeletal muscles (Shoshan-Barmatz et al. 
1996), endoplasmic reticulum (ER) of rat cerebellum (Sho-
shan-Barmatz et al. 2004) and caveolae and caveolae-like 
domains. However, its function in compartments other than 
the mitochondria is less clear.
VDAC1 is overexpressed in many cancer types (Sho-
shan-Barmatz et al. 2015). Thus, VDAC1 is an excellent 
target for anti-cancer therapy since thanks to its observed 
low genetic variability between patients, the chances that 
tumors will develop resistance to VDAC1-based drugs 
by acquiring mutations in VDAC1 are low. The role of 
VDAC1 in cellular metabolism is crucial, since it serves 
as the main interface between mitochondrial and cellular 
metabolisms by allowing a two-way traffic: it mediates the 
entry of metabolites including pyruvate, malate, succinate, 
ADP and NADH into mitochondria and the exit of newly 
formed molecules, such as hemes and ATP (Shoshan-Bar-
matz et al. 2015). Furthermore, VDAC1 is involved in the 
regulation of apoptosis, thanks to its role in the release of 
apoptosis-inducing proteins from the mitochondria to the 
cytosol (Shoshan-Barmatz et al. 2015).
Importantly, downregulation of VDAC1 expression 
resulted in a reduced metabolite exchange between mito-
chondria and the cytosol, inhibited cell growth (Abu-
Hamad et al. 2006) and prevented cell death induced by 
cisplatin (Tajeddine et al. 2008) and endostatin (Yuan et al. 
2008). On the contrary, overexpression of VDAC1 was 
found to induce apoptotic cell death following apoptotic 
stimuli (Godbole et al. 2003; Zaid et al. 2005; Ghosh et al. 
2007; Lu et al. 2007; Abu-Hamad et al. 2008).
The metabolic advantage given by VDAC1 overexpres-
sion to cancer cells is due to the fact that it presents binding 
sites for overexpressed Hexokinase, allowing direct trans-
port of mitochondrial ATP for glucose phosphorylation, 
thus increasing the glycolytic rate, a characteristic of can-
cer cells (i.e., the Warburg effect). In addition, VDAC1 also 
binds Bcl-2 and Bcl-xL, anti-apoptotic proteins expressed 
in many cancer cells, and impacts their cell-saving func-
tion (Shoshan-Barmatz et al. 2015). Bcl-xL was shown 
to interact with VDAC1 to inhibit apoptosis promoted 
by mitochondrial Ca2+ uptake (Roy et al. 2009; Monaco 
et al. 2015). Similary, binding of Bcl-2 to VDAC1 inhib-
its cytochrome c release and apoptosis (Abu-Hamad et al. 
2009). In contrast, other studies showed that VDAC1 inter-
acts with Bax to exert a pro-apoptotic effect (Shimizu et al. 
2000; Shi et al. 2003).
Several studies have shown differences in the expres-
sion of VDAC between cancer cell lines and tissues with 
respect to the normal counterparts: high VDAC1 levels 
were observed in hepatoma, sarcomatous alterations (Yoo 
et al. 2009), non-small-cell lung cancer (NSCLC) cells 
(Brahimi-Horn et al. 2012), gastric cancer cells (Bai et al. 
2011) and different cancer types, such as thyroid, lung, cer-
vix, ovary, pancreas, melanoma and glioblastoma cancers. 
A several-fold increase in VDAC1 expression was shown 
also in peripheral blood mononuclear cells from chronic 
lymphocytic leukemia (CLL) patients (Shoshan-Barmatz 
et al. 2015). In addition, in melanoma and prostate cancer 
cell lines, a positive correlation between levels of VDAC1 
expression and the release of cytochrome c by G3139 was 
demonstrated (Lai et al. 2006). VDAC1 expression was 
also correlated with tumor progression and sensitivity to 
chemotherapy (Simamura et al. 2008; Pernemalm et al. 
2013), whereas gene expression or proteomic analysis of 
NSCLC or primary lung adenocarcinoma patients revealed 
high VDAC1 expression levels as a predictor of poor out-
come (Grills et al. 2011; Pernemalm et al. 2013). Thus, 
determination of VDAC1 expression levels can be useful as 
a molecular biomarker to predict cancer development and 
treatment efficacy.
Several drugs have been shown to interact with VDAC1 
and affect its ability to bind hexokinase and Bcl-2 fam-
ily member proteins (for a recent review, see, e.g., Szabò 
and Zoratti 2014): erastin (Yagoda et al. 2007), oblimersen 
(G3139) (Advani et al. 2011; Pro et al. 2008; Rom et al. 
2009; Lai et al. 2006), avicins (Haridas et al. 2005; Gaik-
wad et al. 2005), cisplatin (Yang et al. 2006; Castagna et al. 
2004), endostatin (Yuan et al. 2008) and methyl jasmonate 
(MJ) (Raviv et al. 2013).
Unfortunately, most of these drugs have pleiotropic 
effects so that their specificity for VDAC1 is not guaran-
teed. Indeed, a more specific approach involving specific 
screening would be required to discover possible novel 
VDAC1 interactors. In this respect, the design of cell-pen-
etrating VDAC1-based peptides (Shoshan-Barmatz et al. 
2015) that impair the interaction between the channel and 
metabolic regulators and thus impact energy homeostasis 
and minimize the self-defense mechanisms of cancer cells 
represents a novel and innovative strategy.
Besides VDAC1, VDAC2 also displays cancer-related 
features. For example, it is also highly expressed in cancer 
lines and tissues, and the main target of erastin (see above) 
is VDAC2. VDAC2 seems to have unique, non-redundant 
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fundamental functions in development and survival, pos-
sibly by impacting the mitochondrial import and OMM-
permeabilizing function of Bak pro-apoptotic Bcl-2 family 
proteins, although VDAC2′s role as a promoter or inhibitor 
of death is still debated (Naghdi and Hajnóczky 2016).
Permeability transition pore (PTP)
The permeability transition pore (PTP) is a voltage- and 
Ca2+-dependent high-conductance channel (1.3 nS in 
150 mM KCl) (Zoratti and Szabò 1995) that is able to dra-
matically increase in the permeability of the IMM to solutes 
with molecular mass up to 1500 Da (Bernardi et al. 2006). 
Indeed, a series of events occurring following PTP open-
ing, including mitochondrial depolarization, generation of 
reactive oxygen species (ROS), release of mitochondrial 
Ca2+ and swelling of mitochondria leading to breaches in 
the OMM that induce the release of intermembrane pro-
teins, promotes this channel as a promising oncological 
target (Rasola and Bernardi 2014). Clearly, long-lasting 
opening of PTP compromises mitochondrial function and 
leads to various forms of cell death (apoptosis, necrosis and 
necroptosis). The key characteristics of PTP are: inhibition 
by CsA, adenine nucleotides, Mg2+, acidic pH and reduc-
ing agents, induction by Ca2+ and voltage sensitivity (Ber-
nardi et al. 1992; Kinnally et al. 1989; Petronilli et al. 1989, 
1991, 1992).
Recently, it has been proposed that the PTP is formed 
by dimers of the FOF1 ATP synthase (Giorgio et al. 2013) 
or by the c-ring of the ATP-producing machinery (Alavian 
et al. 2014). It has recently been demonstrated that purified 
ATP synthase from various organisms forms a channel that 
is similar to the PTP channel and that ablation of e and g 
ATP synthase subunits of the yeast ATP synthase, which 
seems to be required for dimer formation, leads to a marked 
resistance to PTP opening (Carraro et al. 2014). Neverthe-
less, the molecular identity of the PTP is still debated. A 
recent work identified mitochondrial spastic paraplegia 7 
(SPG7), a nuclear-encoded mitochondrial metalloprotease 
(m-AAA) that interacts with cyclophilin D and VDAC1 at 
the IMM and OMM contact site and with a paraplegin-like 
protein AFG3L2 in the IMM, as an essential component of 
PTP (Shanmughapriya et al. 2015, but see also Bernardi 
and Forte 2015). Interestingly, downregulation of SPG7 
expression, however only a minor one, can be observed in 
different cancer tissues (see Table 1): we performed an in 
silico analysis based on the Oncomine® Research Edition, a 
web application that integrates and unifies high-throughput 
cancer-profiling data across a large volume of cancer types, 
subtypes and experiments so that target expression can be 
assessed online, to compare expression of a given protein 
in several cancers compared to normal tissues.
As mentioned above, PTP opening induces apoptosis by 
massive Ca2+ release into the cytosol and by impairment of 
mitochondrial function. The resistance to cell death induc-
tion under stress conditions is a key feature of cell progres-
sion to malignancy (Hanahan and Weinberg 2000, 2011), 
and, indeed, some chemotherapeutics are designed to selec-
tively reactivate apoptosis in cancer cells. PTP inhibition is 
an important adaptation mechanism that acts as a tumor-
enhancer event in the model of hepatocarcinogenesis trig-
gered by 2-acetylaminofluorene in rats (Klohn et al. 2003).
Therefore, comprehension of the PTP structure and 
regulation in cancer progression as well as identification 
of selective PTP activators is very important to develop 
anti-neoplastic strategies. However, it has to be mentioned, 
that the possibility of a selective action on ATP synthase 
only in cancer cells seems unlikely. Nevertheless, several 
compounds that open the PTP are under scrutiny as poten-
tial chemotherapeutics. Many of them, such as the plant-
derived alkaloid berberine (Zhang et al. 2014), the plant 
hormone methyl jasmonate (Raviv et al. 2013), the mono-
cyclic sesquiterpene alcohol-bisabolol (Cavalieri et al. 
2009), the naphtho-quinone shikonin (Han et al. 2007), 
the triterpenoid betulinic acid (Lena et al. 2009), the con-
stituent of turmeric powder curcumin (Qiu et al. 2014), the 
polyphenolic compounds resveratrol (Ma et al. 2007) and 
honokiol (Li et al. 2007b), are natural compounds that have 
been tested on tumor cell lines and in vivo in preclinical 
animal models, and some of them are currently undergoing 
clinical or pre-clinical trials (Leanza et al. 2014b; Suh et al. 
2013).
Most of the above-mentioned agents display pro-apop-
toptic and anti-neoplastic effects because they induce PTP 
opening due to increased oxidative stress. Cancer cells 
exhibit elevated ROS levels, which are produced by both by 
Table 1  Oncomine analysis of 
SPG7 gene in several human 
cancer tissues. Here are reported 
only tumors in which gene 
expression was changed at least 
twice compare to normal tissues
Gene Tissue Tumor C vs. N References
SPG7 Sarcoma Pleomorphic liposarcoma −2.502 Detwiller et al. (2005)
Ovary Ovarian serous surface papillary carcinoma −2.089 Welsh et al. (2001)
Lung Small cell lung carcinoma −4.506 Bhattacharjee et al. (2001)
Kidney Renal Wilms’ tumor −2.232 Yusenko et al. (2009)
Renal oncocytoma −2.735 Yusenko et al. (2009)
Breast Invasive breast carcinoma −2.278 Finak et al. (2008)
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changes in their metabolism as well as exposure to inappro-
priate oxygen concentrations (Grek and Tew 2010). This 
increased level of ROS must be kept under tight control by 
enhancing antioxidant defenses (De Nicola et al. 2011) in 
order to avoid the ROS’ damaging effects on several cel-
lular structures, especially in the early tumorigenic phases 
(Cairns et al. 2011). Under these conditions, the cellular 
fate is the result of a balance between ROS generation and 
scavenging, and cancer cells are more vulnerable than nor-
mal ones to further oxidative insults. Thus, drugs that act 
on oxidative damage may represent a strategy for selec-
tively targeting cancer cells (Gorrini et al. 2013). Since 
PTP induction causes cell death by oxidative stress (Rasola 
and Bernardi 2011), several pro-oxidant agents that are 
able to open PTP lead on one hand to an increase in intra-
cellular Ca2+ release (due to loss of impermeability) and on 
the other hand to inhibition of ATP-dependent Ca2+ extru-
sion from the plasmamembrane (due to membrane poten-
tial loss and decreased ATP synthesis) (Camello-Almaraz 
et al. 2006). Indeed, mitochondria are the most important 
sites for ROS production. ROS produced by the respiratory 
chain complexes can be exported into the cytosol where 
they can activate the ER-located IP3 and ryanodine recep-
tors, which can release Ca2+ from this intracellular store. 
In turn, this Ca2+ will be (partially) buffered by the MCU. 
Intra-mitochondrial calcium activates synthesis of reduced 
substrates (NADH) by metabolic pathways and accelerates 
the electron transport chain, increasing ROS production, 
which in turn facilitates Ca2+ release by sensitization of 
IP3R and RyR (Camello-Almaraz et al. 2006). Therefore, 
strategies to elicit PTP opening can be envisioned as prom-
ising anti-neoplastic approaches, even if the possibility of 
side effects, e.g., on the nervous system or cardiac tissues, 
must be carefully considered (Leanza et al. 2014b). Con-
versely, CsA inhibition of the PTP promotes skin cancer in 
transplant patients, highlighting the key role of PTP inhibi-
tion in tumor development (Norman et al. 2010).
Interestingly, overexpression of a serine protease inhibi-
tor of the serpin family, called SERPINB3 (SB3), causes 
an antioxidant defense mechanism in cancer cells: SB3 
locates inside the mitochondria where it inhibits respira-
tory complex I, thus blocking ROS generation follow-
ing chemotherapeutic treatment and protecting cells from 
PTP opening (Ciscato et al. 2014). Further links among 
PTP induction, ROS generation and respiratory complexes 
came from studies on the serine/threonine kinase GSK-3, a 
kinase involved in a variety of biological processes. GSK-3 
is constitutively active and exerts an inhibitory effect on 
its targets and can be itself regulated by serine or tyrosine 
phosphorylation (Jope and Johnson 2004; Jope et al. 2007). 
A fraction of the enzyme, called mGSK-3, is located inside 
in the mitochondria (Chiara and Rasola 2013), where it 
down-modulates both the Krebs cycle (Hoshi et al. 1996) 
and oxidative phosphorylation (King et al. 2008), thus 
constituting an integration point for targets acting on PTP 
(Juhaszova et al. 2009; Miura and Miki 2009).
In addition, several lines of evidence connect hexoki-
nase II to the PTP, and, for example, it has been shown that 
detachment of hexokinase II from mitochondria by a selec-
tive peptide induces PTP opening triggered apoptosis in 
several tumor cell models independently of VDAC (Chiara 
et al. 2008).
In general, mitochondrial hexokinase II is a good target 
in anti-cancer strategies, since it is required for tumor ini-
tiation and maintenance in mouse models of K-Ras-driven 
lung cancer, as its ablation in conditional knockout mice 
inhibits tumor growth without side effects (Patra et al. 
2013). However, further studies are needed to better under-
stand whether all compounds that target mitochondrial 
hexokinase II can lead to PTP opening.
Recently, it has been proposed that PTP regulation of 
tumor cells can be regulated also by molecular chaperones. 
In particular, the oncogenic TRAP1 was shown to interact 
with succinate dehydrogenase (SDH), inhibiting succinate 
oxidation and inducing a pseudohypoxic response (i.e., 
HIF1 activation in normoxic conditions) (Sciacovelli et al. 
2013), but also by shielding tumor cells from ROS-induced 
PTP opening and death. A decreased TRAP1 expression 
level was observed in some high-grade tumors. Further-
more, TRAP1 and also the mitochondrial pools of Hsp90 
and Hsp60 were reported to interact with CyPD and pre-
vent its ability to induce the pore opening in tumor cell 
models (Kang et al. 2007; Ghosh et al. 2010). Further work 
is required to dissect the mode of action of each of these 
molecular chaperones on the PTP. In summary, PTP is cer-
tainly one of the most promising intracellular channels as 
an oncological target along with VDACs.
The mitochondrial calcium uniporter (MCU)
Mitochondria act as intracellular conductors of intracel-
lular Ca2+ regulation, shaping, remodeling, relaying and 
decoding Ca2+ signals, because of their ability to rapidly 
and transiently accumulate Ca2+ (Drago et al. 2012). In 
animal cells mitochondria were the first intracellular orga-
nelles to be associated with Ca2+ handling, and well before 
the identification of the MCUC components, their ability 
to rapidly sense Ca2+ signals and to act as localized buff-
ers with a high capacity in the proximity of PM and ER 
Ca2+ channels/transporters has been proven (Rizzuto et al. 
2012). Indeed, mitochondrial Ca2+ uptake, by impact-
ing on local calcium concentrations and on the calcium-
mediated feedback mechanism known to modulate the 
activity of Ca2+ channels, influences the frequency and 
amplitude of cytosolic calcium signals. For example, cal-
cium flux across both the PM/ER-located calcium release 
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induced calcium channel CRAC (Orai1/Stim1) and ER-
located inositol-1,4,5-trisphosphate receptor is influenced 
by the physical vicinity of mitochondria. This proximity, 
sustained by specific contacts, the so-called MAMs (mito-
chondria-associated membranes) via chaperones such as 
sigma receptor 1, in turn sets the extent and duration of the 
mitochondrial calcium increase. In addition, especially in 
large cells, recruitment of mitochondria to specific regions 
seems to be important for constraining Ca2+ signals to 
defined cell domains. As a result, mitochondrial calcium 
uptake has been shown at least in vitro to govern numerous 
patho-physiological processes ranging from insulin secre-
tion, neuronal excitotoxicity and cardiomyocyte function to 
tumorigenesis. The reader is advised to consult excellent, 
recent reviews on this topic (e.g., Rizzuto et al. 2012; Fos-
kett and Philipson 2015).
The mitochondrial calcium uniporter MCU, which 
mediates uptake of this ion into the mitochondria, actively 
sequesters cytosolic calcium. Significant advances in iden-
tifying the molecular players of the mitochondrial Ca2+-
handling machinery have been achieved only during the 
last decade. The finding that a highly Ca2+ selective ion 
channel, displaying a very small conductance of only 5 
pS in 100 mM Ca2+ in vitro recapitulated the key charac-
teristics observed for the mammalian mitochondrial uni-
porter in classical bioenergetic experiments, represented 
a milestone toward the molecular identification of the 
uniporter (Kirichok et al. 2004). The MitoCarta database, 
containing more than 1000 mitochondrial proteins (Pagli-
arini et al. 2008), then provided the basis for the identifi-
cation of several mitochondrial calcium uniporter complex 
(MCUC) components in mammals, including the central 
pore-forming protein MCU (mitochondrial calcium uni-
porter; De Stefani et al. 2011; Baughman et al. 2011). At 
the current stage, MCUC appears to include at least of the 
pore-forming protein MCU, an MCU paralog (MCUb), the 
essential MCU regulator (EMRE), the regulatory MICU 
proteins and, possibly, the mitochondrial calcium uni-
port regulator 1 (MCUR1) in mammals (De Stefani et al. 
2015), unlike in other systems containing a more simplified 
MCUC (Wagner et al. 2016). This complex composition in 
mammals may be the reason why it is still unresolved how 
matrix Ca2+ transients are shaped in vivo. What is known 
from experiments in cells is that Ca2+ elevations in the 
mitochondrial matrix stimulate respiration and ATP synthe-
sis (Denton 2009). Ca2+ overload, by contrast, can trigger 
cell death (Duchen 2000). Increased biosynthesis rates of 
ATP rely on the activation of three mitochondrial dehy-
drogenases by Ca2+ (McCormack et al. 1990). Pyruvate 
dehydrogenase (PDH) (Denton et al. 1972), NAD-isoci-
trate dehydrogenase (NAD-ICDH) (Denton et al. 1978) 
and oxoglutarate dehydrogenase (OGDH) (McCormack 
and Denton 1979) are activated by physiologically relevant 
Ca2+ concentrations (100 nM and 1 µM) in mitochondria 
isolated from mammalian tissues (Denton and McCor-
mack 1980; Denton et al. 1980), and phosphorylation of 
PDH is thought to be modulated by the calcium-sensitive 
phosphatase PDP1. Ca2+ elevations in intact cells result 
in NAD(P) reduction (Duchen 1992, Pralong et al. 1992), 
supporting a central role for Ca2+ -dependent regulation 
of mitochondrial metabolism. PDH activity is regulated 
through reversible, calcium-dependent phosphorylation 
(Holness and Sugden 2003; Tovar-Mendez et al. 2003). The 
mitochondrial [Ca2+] increase evoked by a cytosolic [Ca2+] 
rise leads to an enhanced oxidative phosphorylation as well 
and boosts ATP production. Knock-out of the MCUC regu-
lator MICU1 that results in an increased resting state level 
of Ca2+ in the mitochondrial matrix accordingly alters the 
PDH phosphorylation state in cultured cells (Mallilankara-
man et al. 2012). In addition, lower levels of basal matrix 
calcium in the MCU−/− mice led to markedly increased 
levels of PDH phosphorylation in these animals (Pan et al. 
2013), although the animal model used in this study is 
debated especially in view of the modest phenotype and of 
the fact that viable mice could be obtained only in a mixed 
genetic background (see, e.g., Pendin et al. 2014). The con-
sensus view is that conditional and inducible, tissue-spe-
cific knockout models, as well as viral-based gene-delivery 
systems, will be needed to conclusively assess the real 
physiological impact of mitochondrial calcium homeostasis 
in vivo.
A few recent in vivo studies in fact demonstrate that 
mitochondrial calcium homeostasis is crucial for regulation 
of metabolism and its alterations are linked to pathologies. 
Genetic manipulation of MCU in lower organisms such as 
Zebrafish (Prudent et al. 2013) and Trypanosome brucei 
(Huang et al. 2013) resulted in major developmental and 
energetic defects. In humans, homozygous patents carrying 
a loss-of-function mutation of MICU1 are characterized by 
myopathy, cognitive impairment and extrapyramidal move-
ment disorder (Logan et al. 2014), along with an increased 
agonist-induced mitochondrial Ca2+ uptake at low cyto-
solic Ca2+ concentrations and a decreased cytosolic Ca2+ 
signal. However, at least under resting conditions, the fibro-
blasts from affected individuals do not display defects in 
overall cellular metabolic function, but chronic elevation of 
the mitochondrial matrix Ca2+ load seems to lead to mod-
erate mitochondrial stress, resulting in fragmentation of the 
mitochondrial network. In another work, postnatal manipu-
lation of MCU levels in mice (by using adeno-associated 
virus-mediated gene transfer) demonstrated the contribu-
tion of MCUC to the regulation of skeletal muscle tropism. 
MCU overexpression or downregulation caused muscular 
hypertrophy or atrophy, respectively, likely independently 
of metabolic alterations, but dependent on a novel Ca2+-
dependent mitochondria-to-nucleus signaling pathway via 
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transcriptional regulators (Mammucari et al. 2015). Finally, 
in mice with myocardial MCU inhibition by transgenic 
expression of a dominant-negative (DN) MCU, a strong 
correlation among MCU function, MCU-enhanced oxida-
tive phosphorylation and correct pacemaker cell function 
has been found (Wu et al. 2015).
Besides its physiological role for muscle function, 
MCU has also been implicated in cancer-related pro-
cesses, in particular in the control of metastasis. Recently, 
Hall and colleagues (Hall et al. 2014) found that breast 
cancer patient outcomes were negatively correlated with 
increased MCU Ca2+ conducting pore subunit expres-
sion and decreased MICU1 regulatory subunit expression. 
However, they showed that a widely used breast cancer cell 
line did not require MCU or MICU1 activity for survival 
in contrast to cervical, colon and prostate cancer-derived 
cells. Our research in a publically available database sug-
gests that indeed expression of MCU is often altered only 
slightly in tumoral tissues, in accordance with previous 
findings (Davis et al. 2013) (Table 2). On the other hand, 
Tang et al. (2015) revealed that MCU expression correlates 
with metastasis and invasiveness of breast cancer. MCU 
inhibition by ruthenium red or MCU silencing by siRNA 
abolished migration of breast cancer cells and reduced 
serum- or thapsigargin (TG)-induced store-operated Ca2+ 
entry (SOCE). Serum-induced migrations in these MDA-
MB-231 cells were blocked by SOCE inhibitors, sug-
gesting that MCU plays a critical role in breast cancer 
cell migration by regulating SOCE (Tang et al. 2015). In 
an independent study, MCU expression has been related 
to breast tumor size and lymph node infiltration. Indeed, 
in an MDA-MB-231 xenograft model, ablation of MCU 
induced a reduction in tumor growth and metastasis forma-
tion. The mechanism proposed to account for slower tumor 
progression in MCU-lacking cells envisions reduction in 
mitochondrial ROS production and via HIF-1alpha and 
expression of its target genes, in turn inducing a (Tosatto 
et al. 2016) a decrease in cancer progression genes. In this 
work, HIF-1alpha has been demonstrated to be a major 
effector of MCU, since rescuing HIF-1alpha expression the 
cells restored the tumor cells’ ability to migrate. Finally, it 
has been proposed that a small molecule, AG311, shown 
to retard tumor growth and to reduce lung metastases, 
might induce breast cancer cell death by activating MCU, 
although direct proof is missing (Bastian et al. 2015).
In summary, there is an urgent need to identify phar-
macological agents able to impact mitochondrial calcium 
uptake via their specific action on MCUC components, 
since the so-far used Ruthenium Red and lanthanides 
are wide-spectrum modulators. This task could be much 
greatly helped by structure-activity relationship (SAR) 
studies. Unfortunately, only the structure of the N-termi-
nal part of MCU has not been resolved up to now (Lee 
et al. 2015), and a systematic study linking single-point 
mutations to channel function is also missing. Never-
theless, this issue is of utmost importance, especially in 
view of the emerging patho-physiological importance of 
MCUC.
Mitochondrial Kv1.3
Kv1.3 is a member of the Shaker family of the potassium 
channel (Gutman et al. 2005) and is the most expressed 
channel in the T lymphocytes (Cahalan and Chandy 2009). 
Plasma membrane Kv1.3 and the other members of the Kv 
family control the resting and action potential in excitable 
cells, while in non-excitable tissues it regulates cell vol-
ume and proliferation, but also cell death (Armstrong 2003; 
Gutman et al. 2003; MacKinnon 2003; O’Grady and Lee 
2005; Leanza et al. 2014b).
Kv1.3 has been shown to be expressed in brain, lung, 
thymus, spleen, lymph nodes, fibroblasts, lymphocytes 
(Szabò et al. 2005), tonsils, macrophages (Leanza et al. 
2012b), microglia, oligodendrocytes, osteoclasts, platelets, 
liver, skeletal muscle, hippocampal neurons (Bednarczyk 
et al. 2010), astrocytes, and brown and white fat (Gut-
man et al. 2005; Szabò and Zoratti 2014). Furthermore, 
Kv1.3 displays an altered expression level in various can-
cers (Arcangeli et al. 2009; Comes et al. 2015; Bielanska 
et al. 2009), such as lymphoma (Alizadeh et al. 2000), 
melanoma (Artym and Petty 2002), glioma (Preussat et al. 
2003), breast (Abdul et al. 2003; Jang et al. 2009), prostate 
(Abdul and Hoosein 2006), gastric (Lan et al. 2005) and 
colon cancer (Abdul and Hoosein 2002). Kv1.3 was also 
shown to be present in the mitochondrial inner membrane; 
in particular, it has been shown to be expressed in the pros-
tate and breast cancer cell lines PC3 and MCF-7, respec-
tively, and lymphoma and leukemia cells in the mitochon-
dria (Leanza et al. 2013b; Szabo et al. 2015; Gulbins et al. 
2010).
Table 2  Oncomine analysis of CCDC109A gene in several human cancer tissues. Here are reported only tumors in which gene expression was 
changed at least twice compare to normal tissues
Gene Channel Tissue Tumor C vs. N References
CCDC109A MCU Pancreas Pancreatic carcinoma 3.014 Pei et al. (2009)
3.577 Iacobuzio-Donahue et al. (2003)
Kidney Papillary renal cell carcinoma 2.292 Yusenko et al. (2009)
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Results from the Oncomine database are reported in 
Table 3: Kv1.3 is overexpressed in several tumors that 
affect different organs, such as the kidney, blood, skin, 
brain and esophagus, at least two fold with respect to the 
normal tissues. Changes in Kv1.3 expression in cancer 
cells have been related to epigenetic mechanisms, such as 
DNA methylation, as demonstrated in pancreatic cancer 
(Brevet et al. 2009a) and in poorly differentiated breast 
cancer (Brevet et al. 2009b).
Ten years ago, our group discovered the mitochondrial 
counterpart (mitoKv1.3) of this channel located in the IMM 
(Szabò et al. 2005). Other members of Kv channels have 
also been described in mitochondria, i.e., Kv1.5 and Kv1.1 
(Vicente et al. 2006; Leanza et al. 2013a). MitoKv1.3 medi-
ates an inward potassium flux to the mitochondrial matrix 
and has a role in the organellar K+ cycle that participates 
in the modulation of coupling between ATP synthesis and 
mitochondrial respiration, thus contributing to the regula-
tion of several processes including mitochondrial volume, 
mitochondrial structural integrity and production of ROS 
(Szabò et al. 2012). Moreover, mitoKv1.3 has an impor-
tant role during apoptotic cell death (Szabó et al. 2008). 
In particular, it has been demonstrated that mitoKv1.3 
can interact with pro-apoptotic Bax via a critical lysine 
(lys128) that protrudes into the mitochondrial intermem-
brane space (Annis et al. 2005) following translocation of 
Bax to the outer mitochondrial membrane. Point mutation 
of this lysine into a glutamic acid led to lack of inhibi-
tion of mitoKv1.3 and to a switch in the function of Bax, 
transforming it into an anti-apoptotic protein (Szabò et al. 
2011).
We then provided evidence that pharmacological inhi-
bition of mitoKv1.3 by membrane permeant blockers, the 
psoralens Psora-4 and PAP-1, and the riminophenazine 
clofazimine, is sufficient to trigger apoptotic cell death in 
cancer cells but not in healthy ones (Leanza et al. 2012a, 
2013b, 2014a, Szabo et al. 2015). Inhibition of mitoKv1.3 
induced a block of the potassium flux into the mitochon-
dria inducing mitochondrial membrane hyperpolarization 
followed by reduction of the respiratory chain complexes, 
which causes increased ROS production. ROS can in turn 
activate both PTP inducing mitochondrial membrane depo-
larization and favor the detachment of cytochrome c from 
the cristae and its release in the cytosol activating intrinsic 
cell death pathway (Leanza et al. 2015b).
Cell death was detected both in vitro, even with can-
cer cells lacking pro-apoptotic Bax and Bak, often down-
regulated in tumors, and in vivo. In particular, clofazimine 
reduced the tumor volume by 90 % in an orthotopic mouse 
melanoma model (Leanza et al. 2012a). Furthermore, these 
compounds acted also on primary tumor B-cells obtained 
from patients affected by chronic lymphocytic leukemia 
(CLL), one of the most diffuse forms of leukemia in the 
Western world. Indeed, in ex-in vivo experiments, patho-
logical B-cells underwent cell death while healthy cells 
from the same patients did not. Importantly, these effects 
were also obtained with the B-CLL cells that are mutated in 
p53, or overexpressing anti-apoptotic Bcl-2, and were inde-
pendent of the currently used prognostic factors (ZAP70, 
CD38 and hypersomatic mutation) (Leanza et al. 2013b). 
Moreover, these compounds killed primary tumor B-cells 
even when they were co-cultured together with mesenchy-
mal stromal cells, which mimic the lymph node micro-envi-
ronment, favoring the pathological B-cells’ survival (Szabo 
et al. 2015). The selectivity versus cancer cells, accord-
ing to our experiment-based model, is due to a synergis-
tic effect of mitoKv1.3 inhibition and an increase of ROS: 
reactive oxygen species are often altered in tumor cells 
leading them to more easily reach the critical threshold 
necessary to trigger cell death upon exogenous oxidative 
insult (Ralph et al. 2010). In contrast, normal cells, even if 
an increased ROS production is induced, do not reach the 
threshold and do not undergo apoptosis (Trachootham et al. 
2009). Importantly, the fact that clofazimine is a drug that 
Table 3   Oncomine analysis of 
KCNA3 gene in several human 
cancer tissues. Here are reported 
only tumors in which gene 
expression was changed at least 
twice compare to normal tissues
Gene Channel Tissue Tumor C vs. N References
KCNA3 Kv1.3 Kidney Chromophobe renal cell carcinoma 4.908 Jones et al. (2005)
Renal pelvis urothelial carcinoma 4.315 Jones et al. (2005)
Blood Chronic lymphocytic leukemia 2.368 Rosenwald et al. (2001)
3.180 Basso et al. (2005)
2.197 Haferlach et al. (2010)
T-cell acute lymphoblastic leukemia 2.198 Haferlach et al. (2010)
Primary effusion lymphoma 6.402 Basso et al. (2005)
Mantle cell lymphoma 2.924 Basso et al. (2005)
Marginal zone B-cell lymphoma 2.701 Storz et al. (2003)
Skin Actinic (solar) keratosis 2.667 Nindl et al. (2006)
Brain Classic medulloblastoma 2.289 Pomeroy et al. (2002)
Esophagus Barrett’s esophagus 2.565 Hao et al. (2006)
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is already used in the clinic to treat leprosy and some auto-
immune diseases with a very good safety profile (Cholo 
et al. 2012) leads to the possibility for drug repositioning, 
i.e., for treating Kv1.3-expressing tumors with this drug.
Interestingly, it has recently been demonstrated that 
Kv1.3 channels are localized in the nucleus of several types 
of cancer cells and human brain tissues where they are able 
to regulate the nuclear membrane potential and activation 
of transcription factors, such as phosphorylated CREB 
and c-Fos (Jang et al. 2015). Furthermore, Kv1.3 has been 
shown to be present also in the cis-Golgi, even if its role 
in this intracellular membrane and the eventual connection 
with cancer development have not been investigated yet 
(Zhu et al. 2014).
Mitochondrial BKCa (KCa1.1)
The large-conductance calcium- and voltage-activated 
K+ channel BKCa (KCa1.1) is expressed at the plasma 
membrane of both excitable and non-excitable cells, 
including sensory and epithelial cells. It is also expressed 
in the smooth muscle and cardiac muscle, where it is 
involved in muscle contraction but also in cytoprotec-
tion during ischemia/reperfusion. Furthermore, plasma 
membrane BKCa also has a role in hypertension and can-
cer cell metastasis (Cui et al. 2009; Sah 1996; Eichhorn 
and Dobrev 2007; Félétou 2009; Sokolowski et al. 2011). 
BKCa has also been revealed in intracellular membranes, 
such as the nuclear membrane, ER, Golgi and mitochon-
dria (Singh et al. 2012). The existence of mitoBKCa has 
been proven by electrophysiological experiments, as well 
as by Western blotting, electron microscopy and immu-
nofluorescence (O’Rourke 2007; Szewczyk et al. 2010; 
Douglas et al. 2006; Kathiresan et al. 2009; Piwonska et al. 
2008; Skalska et al. 2008). MitoBKCa has been observed 
in the mitochondria of glioma cell lines, astrocytes as well 
as ventricular cells, skeletal muscle, brain and endothe-
lial cells. The known modulators of the plasma membrane 
channel also act on the mitoBKCa. These compounds can 
be divided into activators, such as calcium, diCl-DHAA 
(Sakamoto et al. 2008), NS1619 (Skalska et al. 2009), 
17-estradiol (Ohya et al. 2005) and hypoxia (Cheng et al. 
2008), or inhibitors, such as charybdotoxin (Gu et al. 2007; 
Skalska et al. 2008), iberiotoxin (Cheng et al. 2008, 2011) 
and paxillin (Heinen et al. 2007a, b), but no drug acting 
exclusively on the mitochondrial channel is available up to 
now.
The role of mitoBKCa in pathophysiological conditions 
seems to consist of the modulation of mitochondrial Ca2+ 
uptake. Indeed, its opening protects against damage to the 
heart and other organs caused by ischemia and reperfu-
sion, possibly by preventing calcium overload (O’Rourke 
2007; Xu et al. 2002). mitoBKCa has also been associated 
with cell death, since Bax can inhibit the channel leading 
to the activation of the MPTP (Cheng et al. 2011). To date, 
no evidence about a possible role of mitoBKCa in cancer 
development has been reported, except for a possible role 
in glioma cell motility after irradiation: BK channel activ-
ity is augmented by increasing the open probability but not 
the number of the channels, which results in activation of 
CaMKII leading to enhanced glioblastoma cell migration 
(Steinle et al. 2011).
Mitochondrial IKCa (KCa3.1)
The intermediate-conductance potassium channel (IKCa 
or KCa3.1) is expressed in various tissues, such as epithe-
lial and endothelial tissues, immune system, sensory neu-
rons and microglia but not in excitable tissues. The IKCa 
is involved in several physiological processes modulat-
ing membrane potential and calcium signaling, includ-
ing cell proliferation and differentiation in numerous cell 
types (Szabò and Zoratti 2014). The most known and used 
blockers are TRAM-34, cyclohexadiene 4 and clotrimazole 
(Wulff and Castle 2010). IKCa showed a different expres-
sion in cancer with respect to normal cells: a possible 
explanation for this variation could be ascribed to changes 
at the transcriptional level. The RE1-silencing zinc-finger 
transcription factor (REST) binds to a 21-bp DNA ele-
ment (RE1) within the regulatory region of its target genes, 
repressing gene expression. REST expression can be 
abnormally regulated in cancer cells (e.g., Shimojo et al. 
2013). There are more than 1300 genes that contain an RE1 
element, including genes that encode proteins of funda-
mental importance for cell function such as ion channels. 
A reduced expression of REST can result in the transcrip-
tional activation of KCa3.1, as observed in vascular cells 
(Cheong et al. 2005). Mutations that compromise REST 
transcriptional repression have been associated with differ-
ent cancers, e.g., with childhood renal cancer (Mahamdallie 
et al. 2015). Thus, one intriguing possibility is that expres-
sion of ion channels in general, including that of IKCa in 
cancer cells, is linked to regulation by functionally altered 
REST.
An intracellular localization for the IKCa (mitoIKCa) in 
the inner mitochondrial membrane of human colon carci-
noma and HeLa cells, as well as in mouse embryonic fibro-
blasts, has been demonstrated by electrophysiology and 
Western blotting (De Marchi et al. 2009; Sassi et al. 2010). 
The plasma membrane channel and mitochondrial one 
seem to have the same structure and physiological proprie-
ties, since also the mitoIKCa is inhibited by TRAM-34 and 
clotrimazole.
The role of mitoIKCa in the IMM has not been inves-
tigated in detail, but it is expected to be similar to the one 
hypothesized for the mitoKv1.3 and other mitochondrial 
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potassium channels, i.e., a contribution to the regulation of 
the organelle membrane potential, volume and ROS pro-
duction. A possible role for the mitoIKCa was also postu-
lated during cell death, even if this channel, contrarily to 
mitoBKCa and mitoKv1.3, did not interact with Bax. Nev-
ertheless, a possible role of mitoIKCa in inducing cell death 
has to be verified, since a connection between IKCa chan-
nels and the intrinsic apoptotic pathway has been observed 
(McFerrin et al. 2012). Furthermore, while TRAM-34 
alone was not able to induce cell death when used at the 
micromolar range, it increased the sensitivity of melanoma 
cells to TRAIL treatment (Quast et al. 2012).
Mitochondrial TWIK‑related acid‑sensitive K+ 
channel‑3 (TASK‑3)
The two-pore K+ (K2P) channels, to which the Tandem of 
P-domains weakly inward rectifying K+ (TWIK)-related 
acid sensitive K+ channel 3 (TASK-3) belongs, is the most 
recently identified group among the K+ channels. K2P 
channels are ‘leak’ K+ channels that set the resting mem-
brane potential and regulate cell excitability (Felipe et al. 
2006; Bayliss and Barrett 2008). TASK-3 is normally found 
in the adrenal cortex, gastrointestinal tract, neuronal tissue 
and salivary glands (Bayliss and Barrett 2008; Kovacs et al. 
2005) and is modulated by alterations in extracellular pH 
and by anaesthetic agents; it plays a role in aldosterone 
secretion (Bayliss and Barrett 2008; Bayliss et al. 2003; 
Ekhterae et al. 2003; Patel and Lazdunski 2004). Altered 
TASK-3 expression has already been defined in several 
types of cancer, i.e., breast cancer, and the gene encoding 
TASK-3 (KCNK9) was found to be overexpressed by 5- 
to >100-fold in 44 % of tumors (Mu et al. 2003). TASK-3 
expression has also been identified in mitochondria of 
melanoma, keratinocytes (Rusznák et al. 2008) and healthy 
intestinal epithelial cells (Kovacs et al. 2005). Furthermore, 
this channel is also expressed in lung, colon and ovarian 
cancers (Felipe et al. 2006; Kim et al. APMIS 2004; Poc-
sai et al. 2006; Innamaa et al. 2013). Silencing the expres-
sion of TASK-3 resulted in compromised mitochondrial 
function, i.e., mitochondrial membrane depolarization, 
and reduced cell survival inducing apoptotic cell death in 
WM35 and A2058 melanoma cells (Kosztka et al. 2011; 
Nagy et al. 2014). Two aspects linked TASK-3 to cancer 
development or treatment: (1) observed migration and inva-
sion-reducing effects of TASK-3 overexpression in breast 
cancer cells (Lee et al. 2012) and (2) increased apoptosis 
induced by TASK-3 blockers (zinc and methanandamide) 
in ovarian carcinoma (Innamaa et al. 2013). Further inves-
tigation will be necessary to understand whether these 
effects are related to the mitochondrial channel expres-
sion and whether it is possible to pharmacologically regu-
late mtTASK-3 causing tumor cell death. Since no highly 
specific mtTASK-3 modulators are available, this aim is 
difficult to investigate, and the only advance in this field is 
represented by dihydropyrrolo[2,1-α]isoquinolines (DPIs) 
compounds, which are able to inhibit TASK channels and 
could be possible candidates for developing new specific 
inhibitors (Noriega-Navarro et al. 2014).
Mitochondrial magnesium channel Mrs2
Mitochondria not only store calcium, but also take up mag-
nesium to maintain the optimal cytosolic Mg2+ concentra-
tion (0.5–0.7 mM) (Kubota et al. 2005). Mg2+ can be accu-
mulated inside the mitochondria via the Mg2+-selective 
channel of the inner mitochondrial membrane (Kolisek 
et al. 2003), which takes advantage of the driving force 
produced by the mitochondrial membrane potential and 
is feedback regulated by the increasing Mg2+ concentra-
tion in the matrix (Khan et al. 2010). An early increase in 
cytosolic Mg2+, which also favors cytochrome c release, 
occurs during apoptotic cell death (Chien et al. 1999; Kim 
et al. 2000). Moreover, knockdown of the mitochondrial 
magnesium channel (Mrs2) caused cell death by inducing 
loss of respiratory complex I and mitochondrial membrane 
depolarization (Piskacek et al. 2009). On the contrary, an 
upregulation of Mrs2 has been observed in parental human 
gastric adenocarcinoma cell lines, indicating that high 
expression of Mrs2 may protect against death (Chen et al. 
2009; Wolf and Trapani 2009). In agreement, an augmented 
expression of the mrs2 gene has been reported by compar-
ing normal and cancer organs as shown in Table 4: a gen-
eral increase of around two-three-fold (but in testis tumor a 
17-fold increase) has been observed in blood, skin, ovarian, 
kidney, breast, lung and bladder tumors when compared to 
the normal tissues, meaning that it would be worthwhile 
to further deepen our understanding of the possible role 
of mitochondrial Mg2+ fluxes in cancer development (see 
Table 4 and the references therein).
Mitochondrial uncoupling protein UCP
The Uncoupling protein (UCP) family is constituted by five 
members and belongs to the mitochondrial anion-carrier 
proteins (Krauss et al. 2005). UCPs are inner mitochondrial 
membrane proteins involved in the re-entry of protons into 
the mitochondrial matrix, partially dissipating the electro-
chemical gradient and therefore the mitochondrial mem-
brane potential. As a consequence, UCP2 regulates mito-
chondrial ROS production as well. UCP-2 is ubiquitously 
expressed in different tissues, including skeletal muscle and 
β-cells, and it is overexpressed in numerous tumors, such 
as breast, ovarian, bladder, esophagus, testicular, colorectal, 
kidney, pancreatic, lung and prostate cancers and leukemia 
(Leanza et al. 2014b).
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UCP2 has been proposed to impact cell survival by 
decreasing the formation of mitochondrial superoxide 
production by tuning the proton leak and thus the mito-
chondrial membrane potential (Baffy 2010; Baffy et al. 
2011; Basu Ball et al. 2011; Deniaud et al. 2012). Indeed, 
UCP2 overexpression protects against ROS production and 
increases the apoptotic threshold for cancer cell survival 
(Zhang et al. 2007), while UCP2 knockdown or pharma-
cological inhibition leads to an increase in mitochondrial 
ROS, as observed in UCP2 knockout mice (Arsenijevic 
et al. 2000). Moreover, UCP2 downregulation or inhibition 
triggers an ROS-mediated autophagy in pancreatic adeno-
carcinoma cells (Dando et al. 2013).
UCP2 overexpression has been observed after oxida-
tive stress induced by respiratory chain inhibitors (Giardina 
et al. 2008) and has been related to the development of 
breast cancer in an orthotopic model (Ayyasamy et al. 
2011). Furthermore, UCP-2 overexpression was correlated 
with the Warburg phenotype (Samudio et al. 2008). Addi-
tionally, UCP2 was proposed to catalyze an exchange of 
malate, oxaloacetate and aspartate for phosphate; it exports 
C4 metabolites from mitochondria to the cytosol in vivo, 
providing evidence that UCP2 reduces mitochondrial oxi-
dation of glucose and enhances glutaminolysis. These 
results postulate a unique regulatory mechanism in cell bio-
energetics and explain the significance of UCP2 levels in 
metabolic reprogramming occurring under various physio-
pathological conditions (Vozza et al. 2014).
Importantly, UCP2 overexpression prevented the death-
inducing effect of chemotherapy in different cancer cell 
lines: indeed, treatment with gemcitabine stimulates UCP2 
mRNA production, suggesting a role of mitochondrial 
uncoupling in the resistance to this chemotherapeutic agent, 
and pointed out the possible synergistic antiproliferative 
effect of coupling gemcitabine treatment and UCP2 inhibi-
tion (Derdak et al. 2008; Dalla Pozza et al. 2012; Yu et al. 
2015a). Onconase, a member of the RNase super-family, is 
able to inhibit UCP2 and manganese-dependent superoxide 
dismutase (MnSOD), thus triggering mitochondrial super-
oxide ion production leading to autophagy (Fiorini et al. 
2015). Similarly, a decrease in cell viability and clono-
genicity, in addition to an increase in ΔΨm, ROS produc-
tion, apoptosis and autophagy, was induced in breast cancer 
cells after both UCP2 inhibition by siRNA and cytotoxic 
Table 4  Oncomine analysis of MRS2 gene in several human cancer tissues. Here are reported only tumors in which gene expression was 
changed at least twice compare to normal tissues
Gene Channel Tissue Tumor C vs. N References
MRS2 Mrs2 Testis Testicular embryonal carcinoma 17.178 Skotheim et al. (2005)
9.762 Korkola et al. (2006)
Testicular seminoma 3.812 Skotheim et al. (2005)
3.281 Korkola et al. (2006)
Testicular intratubular germ cell neoplasia 2.754 Skotheim et al. (2005)
Testicular yolk sac tumor 2.213 Skotheim et al. (2005)
4.199 Korkola et al. (2006)
Testicular teratoma 2.006 Skotheim et al. (2005)
Skin Skin basal cell carcinoma 3.487 Riker et al. (2008)
Cutaneous melanoma 3.469 Riker et al. (2008)
Skin squamous cell carcinoma 2.056 Riker et al. (2008)
Ovarian Ovarian serous adenocarcinoma 3.105 Yoshihara et al. (2009)
Kidney Papillary renal cell carcinoma 3.070 Yusenko et al. (2009)
Chromophobe renal cell carcinoma 2.283 Yusenko et al. (2009)
Breast Ductal breast carcinoma 2.775 Richardson et al. (2006)
Ductal breast carcinoma in situ 2.049 Ma et al. (2009)
Invasive breast carcinoma 2.376 Finak et al. (2008)
Blood T-cell childhood acute lymphoblastic leukemia 2.517 Coustan-Smith et al. (2011)
B-cell childhood acute lymphoblastic leukemia 2.036 Coustan-Smith et al. (2011)
Anaplastic large cell lymphoma 2.400 Piccaluga et al. (2007)
Angioimmunoblastic T-cell lymphoma 2.023 Piccaluga et al. (2007)
Lung Pleural malignant mesothelioma 2.458 Gordon et al. (2005)
Bladder Superficial bladder cancer 2.440 Dyrskjøt et al. (2004)
Infiltrating bladder urothelial carcinoma 2.073 Dyrskjøt et al. (2004)
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treatments by tamoxifen (Gabriel Pons et al. 2015). Like-
wise, MiR-214 sensitizes breast cancer cells to both tamox-
ifen and fulvestrant treatment by targeting UCP2 (Yu et al. 
2015b). Finally, UCP3 has been linked to clear cell renal 
cell carcinoma: it has been proposed that inhibition of 
UCP3 by ADP might contribute to the setting of the endog-
enous mitochondrial membrane potential (Lim et al. 2015).
In summary, modulation of oxidative stress in cancer 
cells is a powerful tool to kill or at least sensitize them 
to chemotherapeutic treatments, as has been observed 
with mitoKv1.3. In this scenario, a primary role could be 
attributed to UCP proteins, especially to UCP2 and UCP3.
Intracellular chloride channel CLIC‑4
An emerging class of chloride-permeable channels involved 
in cancer development is the intracellular chloride chan-
nels (CLICs). In particular, chloride intracellular channel 4 
(CLIC4) is the most well-characterized member of a fam-
ily of channel proteins that is highly conserved from Cae-
norhabditis elegans to humans. The intracellular CLIC4/
mtCLIC has both soluble and membrane-inserted forms 
and can be localized in different subcellular compartments, 
such as the mitochondrial inner membrane (Fernández-
Salas et al. 1999), cytoplasm, ER membrane, and nucleus. 
The expression of the CLIC4 transcript is regulated by p53 
and tumor necrosis factor α (TNFα), and clic4 is a direct 
response gene for both c-myc and p53, two mediators of 
cancer pathogenesis in multiple tumor sites (Peretti et al. 
2015).
CLIC4 overexpression induced apoptotic cell death 
mediated by loss of the mitochondrial membrane potential, 
cytochrome c release and caspase activation (Fernández-
Salas et al. 2002). On the other hand, inhibition of CLIC4 
expression triggered mitochondrial apoptosis under star-
vation and enhanced autophagy in human glioma cells 
(Zhong et al. 2012; Xu et al. 2013). Marked changes in 
expression and subcellular localization of CLIC4 occur 
early in tumorigenesis: (1) CLIC4 expression was reported 
to be a marker of colon cancer stem cells and is associ-
ated with a poor prognosis, (Deng et al. 2014); (2) reduced 
CLIC4 expression and nuclear translocation, following cel-
lular stress conditions, e.g., DNA damage, senescence and 
metabolic alterations, is associated with the altered redox 
state, and CLIC4 acts as an important suppressor of cuta-
neous squamous cell cancer development and progression 
(Suh et al. 2012); (3) KRAS-mediated downregulation of 
CLIC4 may promote cancer carcinogenesis in a specific 
fraction of lung cancers (Okudela et al. 2014). Moreover, 
circulating CLIC4 was identified as a biomarker for epi-
thelial ovarian cancer (Tang et al. 2013). Thus, in addition 
to an important function in cancer pathogenesis as a tumor 
suppressor, CLIC4 is emerging as a potential biomarker 
to monitor tumor progression and recurrence in multiple 
human cancers.
Intracellular potassium channel Kv10.1
A surprising localization of the human ether à-go-go1 pro-
tein (Eag1 or Kv10.1), a potassium voltage-gated channel 
subfamily H member 1, has been described in the nuclear 
inner membrane (Chen et al. 2011). There, the channel 
seems to be involved in setting the nuclear K+ concentra-
tion thereby affecting gene expression, as postulated also 
for the nuclear Kv1.3. Even if expressed in the plasma 
membrane, Kv10.1 is also rapidly internalized to lys-
osomes (Kohl et al. 2011), as demonstrated also by patch 
clamp measures (Wang et al. 2012).
An increased expression of Kv10.1 can be triggered 
by the tumor suppressor p53, as observed in glioblastoma 
(Bai et al. 2013), and the transcription factor E2F1 (Lin 
et al. 2011). Overexpressed Kv10.1 controls cancer cell 
migration and proliferation by interactions with RAB pro-
teins (Ninkovic et al. 2012), cortactin (CTTN) and focal 
adhesion kinase (FAK) (Herrmann et al. 2012) as well as 
through calcium signaling (Hammadi et al. 2012) and an 
altered response to hypoxia (Downie et al. 2008). Overex-
pression by genomic amplification has been implicated as 
a mechanism of Kv10.1 involvement in a small proportion 
of colon (3.4 %) and head and neck (15 %) cancers (Pardo 
and Stühmer 2014).
Eag1 is not detectable in healthy tissues except the 
brain, but its overexpression, not discriminating between 
the plasma membrane and intracellular channels, has been 
detected at a very high rate (>75 %) in several tumors: breast, 
renal and cervical carcinoma cell lines, as well as in differ-
ent human malignancies, for instance, colorectal and cervi-
cal cancer, soft tissue sarcomas, acute myeloid leukemia, 
esophageal and gastric cancer, head and neck carcinomas, 
ovarian, breast, lung and prostate cancer and glioblastoma 
(Martínez et al. 2015 and references therein). Importantly, 
Kv10.1 expression correlates with poor prognosis in fibro-
sarcoma, ovarian carcinoma, acute myeloid leukemia (AML) 
and colon, head and neck cancer (Pardo and Stühmer 2014).
Furthermore, Kv10.1 transfection in healthy cells 
induces transformation and leads the transfected cells to 
develop invasive tumors in vivo: this was the first obser-
vation of the oncogenic capacity of a potassium channel 
(Pardo et al. 1999). Interestingly, a Kv10.1 mutant that 
lacks potassium permeability reduces, but does not abol-
ish tumorigenesis (Downie et al. 2008; Hegle et al. 2006). 
Despite all these observations, the exact contribution of 
the intracellular Eag1 to cancer cell survival remains to be 
determined.
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Intracellular Transient Receptor Potential 
Channel (TRPs)
The transient receptor potential (TRP) channel superfam-
ily is one of the largest families of cation channels (Nilius 
and Owsianik 2011). The TRP family is constituted by 
28 members, divided into subfamilies, which are TRPC 
(canonical), TRPM (melastatin), TRPP (polycystin), TRPV 
(vanilloid), TRPML (mucolipin) and TRPA (ankyrin-like) 
(Nilius 2007). Among them, the intracellularly located 
channels that are related to cancer development and pro-
gression identified so far are TRPM8 and TRPC1.
The calcium-permeable TRPM8 is located in the endo-
plasmatic reticulum (ER) membrane and is overexpressed 
in several tumors (Zhang and Barritt 2004). TRPM8 traf-
ficking is mediated during carcinogenesis by interaction 
and consequent regulation by TRPM8 channel-associ-
ated factor 1 and 2 (TCAF-1 and TCAF-2). In particular, 
TCAF-1 is more expressed in the early tumor stages favor-
ing cancer development, while its expression as well as 
that of TRPM8 is reduced during the tumor spreading with 
metastasis (Gkika et al. 2015). Intracellular TRPM8 medi-
ates the decrease in Ca2+ concentration inside the ER and 
favors the resistance to apoptotic cell death (Bidaux et al. 
2007). As mentioned above, an increase in intracellular 
Ca2+ leads to modulation of the signaling pathways and to 
transcription of genes that mediate the cellular responses to 
mitogens and chemoattractants.
TRPM8 expression in normal conditions is tissue-selec-
tive, while when TRPM8 is abnormally expressed, it has 
been observed in several different cancer tissues, such as 
prostatic, pancreatic, breast and colorectal ones, in urinary 
bladder and oral squamous cells, and in lung carcinoma, 
melanoma, neuroblastoma and osteosarcoma (Yee 2015). 
In particular, expression of TRPM8 in breast carcinoma 
correlates with the histological grade, Ki-67, tumor size 
and expression of the estrogen receptor. These findings 
suggest that TRPM8 channels play a pivotal role in the 
development and growth of mammary tumors (Dhennin-
Duthille et al. 2011; Chodon et al. 2012; Liu et al. 2014). 
Experimental data demonstrated that TRPM8 channels play 
important roles in general in cancer cells, in particular in 
their proliferation, survival, migration, invasion and neu-
rosecretion. For example, the regulation of proliferation in 
cancer cell lines has been proven by siRNA experiments, 
in which downregulation of TRPM8 caused the reduction 
of prostatic and osteosarcoma cancer cell proliferation 
and cell cycle progression (Valero et al. 2012; Wang et al. 
2014). On the other hand, in lung carcinoma, the ectopic 
expression of TRPM8 favors cell propagation (Du et al. 
2014). These data suggest a tumor-specific role of TRPM8 
in proliferation. Furthermore, several in vivo studies have 
linked TRPM8 to cancer growth and metastasis (Yee 2015). 
The aberrant overexpression of TRPM8 in tumors and its 
proliferative and invasive roles suggest a future develop-
ment of the TRPM8 channel as a prognostic/predictive bio-
marker and a therapeutic target in oncology.
Another member of this superfamily located in the ER is 
TRPC1. This was the first and most studied member in the 
context of cancer, being involved in several features of can-
cer cells, such as cell fate and motility (Shapovalov et al. 
2016). This channel has a specific regulation in cancer, 
also depending on the stage of malignant transformation: 
the TRPC1 expression level decreases with the progres-
sion of the prostate cancer from the androgen-dependent to 
androgenin dependent phase (Nilius et al. 2007). The role 
of TRPC1 in cancer progression is predominantly related to 
cell motility. In particular, inhibition of expression and/or 
activity in nasopharyngeal carcinoma led to reduced adhe-
sion and invasiveness of cancer cells (He et al. 2012). Fur-
thermore, pharmacological inhibitors, such as SKF96365, 
2-APB and MRS1845, or siRNA against TRPC1 was able 
to suppress human malignant glioma proliferation (Bom-
ben and Sontheimer 2010). Similar effects have also been 
found in a lung carcinoma cell line, in which TRPC1 abla-
tion by siRNA induced blocking of cell growth due to G0/
G1 cell cycle arrest (Bomben et al. 2011).
Intracellular IP3 receptors
The two major families of Ca2+ channels involved in 
the release of this cation from the ER include the inositol 
1,4,5-trisphosphate receptors (IP3Rs) and ryanodine recep-
tors (RyRs). In cancer cells, Ca2+ mobilization has been 
observed to contribute to tumor progression, and increasing 
numbers of studies indicate the relevance of IP3Rs to can-
cer. (Prevarskaya et al. 2011; Roderick and Cook 2008; Lee 
et al. 2011; Monteith et al. 2012). Indeed, type 1 IP3R (i.e., 
IP3R1) expression is reduced and type 3 IP3R (i.e., IP3R3) 
expression is increased in human glioblastoma tissues com-
pared to normal human brain, and inhibition of IP3R3 by 
caffeine reduces the migration, invasion and survival of 
glioblastoma cells (Kang et al. 2010). Similar effects as the 
one induced by caffeine have been observed in breast can-
cer cells in the presence of 17β-estradiol (E2) (Szatkowski 
et al. 2010). Increased IP3R3 expression was also related 
to aggressiveness in colorectal cancer: high levels of IP3R 
were associated with increased metastasis in the lymph 
nodes and liver and a decreased 5-year survival (Shibao 
et al. 2010). Moreover, changes in IP3R1 have been impli-
cated in the biological properties of the tumors: for exam-
ple, cisplatin-induced downregulation of IP3R1 expression 
was found to be associated with the acquisition of cisplatin 
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resistance in bladder cancer cell lines (Tsunoda et al. 2005). 
Furthermore, Bcl-2 family proteins, which have pro- and 
anti-apoptotic functions, directly bind to different sites on 
IP3Rs and impact IP3R function, suggesting that IP3R is 
an important hub for the action of Bcl-2 family proteins in 
various physiological and pathological settings including 
tumor progression (Seo et al. 2015; Oakes et al. 2005; Letai 
2008). In addition, other proto-oncogenes as well as tumor 
suppressors, such as Akt/protein kinase B (PKB) (Chan 
and Tsichlis 2001), Bax inhibitor-1 (BI-1) (Li et al. 2007a; 
Eckenrode et al. 2010) and K-ras-induced actin-interacting 
protein (KRAP) (Fujimoto et al. 2011), modulate cancer 
development by acting on Ca2+ fluxes mediated by the 
IP3Rs (Akl and Bultynck 2013). Currently, little is known 
about what specific players of Ca2+ signaling contribute to 
the altered Ca2+ mobilization in cancer cells and how Ca2+ 
signaling cross-talks with well-known cancer pathways, 
such as the Ras/Raf/MAPK pathway (Dhillon et al. 2007). 
Recently, a paper has connected the Ras signaling pathway, 
often deregulated in cancer (Downward 2003), to the IP3R-
mediated Ca2+ release pathway. Indeed, oncogenic K-Ras 
inhibited IP3-induced Ca2+ release from the ER by remod-
eling of IP3R isoform composition in a human colorectal 
cancer cell line harboring the K-Ras mutant allele (G13D) 
(Pierro et al. 2014). A further link between K-Ras and IP3R 
is suggested by the finding that K—the GTP-bound active 
form of K-Ras4B—forms a ternary complex with IP3R and 
Bcl-xL and promotes cell death, indicating that IP3R is a 
novel effector of K-Ras4B. (Sung et al. 2013).
Finally, IP3Rs have also been shown to interact with 
other ion channels. Indeed, IP3R3 is able to favor breast 
cancer cell proliferation by co-localizing and directly inter-
acting with BKCa channels, but only in cancerous cells and 
not in the healthy ones (Mound et al. 2013).
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